Moderna, Inc. (NASDAQ:MRNA) Stock Holdings Lowered by Moloney Securities Asset Management LLC

Moloney Securities Asset Management LLC trimmed its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 52.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 4,854 shares of the company’s stock after selling 5,406 shares during the quarter. Moloney Securities Asset Management LLC’s holdings in Moderna were worth $202,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in MRNA. Wilmington Savings Fund Society FSB boosted its stake in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after acquiring an additional 587 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after purchasing an additional 389 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of Moderna by 53.1% during the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock valued at $47,000 after purchasing an additional 388 shares during the last quarter. EMC Capital Management increased its stake in Moderna by 311.2% in the 4th quarter. EMC Capital Management now owns 1,250 shares of the company’s stock worth $52,000 after purchasing an additional 946 shares in the last quarter. Finally, Larson Financial Group LLC raised its holdings in Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after buying an additional 317 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Trading Down 2.9 %

Moderna stock opened at $30.93 on Wednesday. Moderna, Inc. has a one year low of $30.70 and a one year high of $170.47. The company’s fifty day moving average price is $39.77 and its two-hundred day moving average price is $56.76. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The company has a market capitalization of $11.90 billion, a price-to-earnings ratio of -5.31 and a beta of 1.59.

Analysts Set New Price Targets

Several brokerages have commented on MRNA. The Goldman Sachs Group cut shares of Moderna from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Argus cut shares of Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Leerink Partners reduced their target price on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a report on Thursday, January 16th. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Finally, Bank of America reduced their price objective on Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research note on Tuesday. Four analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Moderna has an average rating of “Hold” and an average target price of $66.89.

Insider Transactions at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last quarter, insiders sold 2,664 shares of company stock worth $115,210. 15.20% of the stock is owned by corporate insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.